Pfizer's surprise Remoxy withdrawal slashes Pain, Durect prices by half

Pfizer has left its partner Pain Therapeutics shocked by an unexpected decision to withdraw from a deal between the two companies relating to opioid agonist Remoxy. Investors too were left reeling, sending shares of both Pain Therapeutics and Durect, the developer of the technology behind Remoxy, plummeting.